ASCO GU Conference Coverage
Featured News
(CNN) Feb 16, 2019 - The way doctors typically approach kidney cancer treatment could be evolving. Two separate studies published Saturday in the New England Journal of Medicine showed that renal cell cancer patients had significantly better outcomes when their treatment combined the targeted therapy drug axitinib, or Inlyta, with an...
(Reuters) Feb 16, 2019 - A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the...
(Dana-Farber) Feb 16, 2019 - A combination of two drugs -- one of them an immunotherapy agent -- could become a new standard, first-line treatment for patients with metastatic kidney cancer, results from a phase 3 clinical trial suggest. Patients who received the immunotherapy drug avelumab plus axitinib, a VEGF targeted agent, had a...
(Pharmaphorum.com [UK]) Feb 15, 2019 - Bayer and development partner Orion have released detailed results from the trial that will form the backbone of its filing for their latest prostate cancer drug, as they aim to take on two established blockbusters from Johnson & Johnson and Pfizer/Astellas. J&J and Astellas market androgen...
(BioSpace) Feb 14, 2019 - Merck is increasing its focus on developing therapies for advanced prostate cancer with its powerful checkpoint inhibitor Keytruda. The pharma giant announced plans to expand its immuno-oncology program with three new Phase III trials following promising data from a combination of Keytruda and Lynparza and other...
(BioSpace) Feb 12, 2019 - The American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) is being held in San Francisco from February 14-16. Ahead of the conference, several companies have announced presentations. Here’s a look at just a few. Merck & Company. Merck plans to present survival data from its...
(Vantage) Feb 11, 2019 - In the Keynote-426 study Merck & Co’s Keytruda looks to have blasted Opdivo out of the water, showing a 47% reduction in risk of death versus Sutent. Bristol-Myers Squibb is probably getting tired of this, but it’s happened again. Another oncology setting in which Opdivo had seized an early foothold, in...
(2019 GU Cancers Symposium) Feb 11, 2019 - A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite standard therapies, found that in the majority of men, the cancers were responsive to treatment with a novel, targeted radiation therapy called Lutetium-177...
(Duke Health) Feb 12, 2019 - It used to be a statistical fact that African-American men fared worse than whites when battling prostate cancer. But recent research led by scientists at the Duke Cancer Institute has been challenging that notion. Added evidence will be presented Feb. 11 at a meeting of the American Society of Clinical...
View all
More News
(NCI/Cancer Currents Blog) Mar 15, 2019 - The investigational drug darolutamide can help delay the spread of prostate cancer in some men with the disease, a recent clinical trial shows. In addition, the drug caused fewer side effects than similar prostate cancer drugs.
(MarketWatch) Feb 22, 2019 - Accuray Incorporated announced today that data from an international, randomized, 38-center trial (PACE - Prostate Advances in Comparative Evidence) show that treatment with stereotactic body radiation therapy (SBRT) results in a similar safety profile to conventional radiation in men with low- or...
(Merck) Feb 16, 2019 - Merck, known as MSD outside the United States and Canada, today announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced...
(Pfizer) Feb 16, 2019 - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression. US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell carcinoma. Data at 2019 Genitourinary Cancers Symposium reinforce...
(MedPage Today) Feb 16, 2019 - In two early trials, monoclonal antibody-drug conjugates showed activity in metastatic bladder cancer patients that had failed on checkpoint inhibitors, researchers reported.
(BioSpace) Feb 15, 2019 - As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
(NASDAQ) Feb 15, 2019 - Nektar Therapeutics announced today a presentation of new clinical data for bempegaldesleukin1 (NKTR-214) in combination with nivolumab in patients with first-line (1L) advanced or metastatic urothelial carcinoma at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) in San...
(MarketWatch) Feb 16, 2019 - AVEO Oncology today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC).
(Yahoo! Finance) Feb 16, 2019 - Clinical study explored Calithera’s lead compound in combination with cabozantinib in patients with advanced renal cell carcinoma.
(Yahoo! Finance) Feb 19, 2019 - Encouraging preliminary signs of efficacy, including one complete response, observed in patients with advanced bladder cancer who have progressed on multiple prior treatments including immunotherapy and gemcitabine.
(National Cancer Centre Singapore) Feb 15, 2019 - Study was conducted on 36 kidney cancer patients using the CLEARScore™ test that identifies eight genes linked to immunotherapy.
(Yahoo! Finance) Feb 15, 2019 - Data to be Presented at the Annual ASCO Genitourinary Cancers Symposium. Data to further support clinical adoption of SelectMDx and ConfirmMDx.
Featured Videos
There are no featured ASCO GU Conference Coverage videos.

OBR Tweets

Jul 09
H. Jack West, MD: The benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but th… https://t.co/8wOgsSCY7q

Jul 08
Howard S. Hochster, MD: While a "complete response" is great for our patients, the Complete Response Letter was les… https://t.co/yQGkfvpMCF

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY

Jul 01
A report on several promising studies at #ASCO20 focused on personalized therapies for patients with unmet needs. I… https://t.co/lc4BoQ3Evl

Jul 01
At #ASCO’s virtual meeting, studies featured potentially practice-changing data. Among the studies were the BOSTON… https://t.co/6pXpxFomwu

Jun 22
Howard S. Hochster, MD: Another, but far more problematic approval for Pembro. Which tumors actually have high TMB… https://t.co/pBSquns9mN

Jun 19
Dean Gesme, MD: The positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E… https://t.co/GXnYhO8jov

Jun 17
Thomas Marsland, MD: I actually enjoyed the experience. I certainly missed mingling with friends and colleagues. Al… https://t.co/gVtYjkzPzy

Jun 16
Derek Raghavan, MD, on @LevineCancer provides a general overview of prostate cancer therapies #ASCO20 https://t.co/niwz0yPHjB

Jun 16
H. Jack West, MD: We await phase 3 data, but many will welcome a new option with an approximately 35% response rate… https://t.co/Ld5N8KrWye